{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:11:59Z","timestamp":1791994319181,"version":"4.4.0"},"reference-count":14,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T00:00:00Z","timestamp":1772236800000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013170","name":"Ono Pharmaceutical Co., Ltd","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100013170","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Triplet therapy (encorafenib, cetuximab, and binimetinib) is recommended in Japan for BRAF V600E mutated metastatic colorectal cancer (mCRC) patients with poor prognostic factors (PFs) based on subgroup analyses of the BEACON CRC trial. We, therefore, conducted a nationwide prospective observational study to evaluate the real-world effectiveness of triplet versus doublet therapy (encorafenib plus cetuximab).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>The BEETS trial (UMIN000045530) enrolled BRAF-mutated mCRC patients who received triplet or doublet as second- or third-line treatment. The primary endpoint was overall survival (OS). Exploratory analyses using inverse probability weighting (IPW) based on propensity scores were performed to adjust for poor PFs (ECOG performance status \u22651, \u22653 metastatic sites, elevated C-reactive protein, or unresected primary tumor).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In 203 enrolled patients, 195 patients were evaluable. Median age was 67\u2009years; 52% were male. Dose intensity for encorafenib and cetuximab was comparable between the triplet and doublet cohorts. In the overall cohort, median OS and progression-free survival (PFS) were 12.9 and 4.9\u2009months, respectively. After IPW adjustment, median OS was 14.0\u2009months in the triplet cohort and 12.9\u2009months in the doublet cohort (HR 0.87, 95%CI 0.57-1.33). Median PFS was 5.3 versus 4.2\u2009months (HR 0.75, 95%CI 0.48-1.19). Among patients with at least one poor PF, both OS and PFS numerically favored the triplet regimen.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In real-world clinical practice, triplet and doublet therapies showed comparable survival outcomes, consistent with the BEACON trial. Triplet therapy may provide potential clinical benefit in patients with poor PFs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyag068","type":"journal-article","created":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T12:50:33Z","timestamp":1772023833000},"source":"Crossref","is-referenced-by-count":1,"title":["Real-world outcomes of encorafenib, cetuximab \u00b1 binimetinib for\n                    <i>BRAF<\/i>\n                    \u2011mutated metastatic colorectal cancer: the BEETS (JACCRO CC\u201118) study"],"prefix":"10.1093","volume":"31","author":[{"given":"Daisuke","family":"Kotani","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East , Kashiwa, 277-8577,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eisuke","family":"Inoue","sequence":"additional","affiliation":[{"name":"Showa Medical University Research Administration Center, Showa Medical University , Tokyo, 142-8555,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadamichi","family":"Denda","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Chiba Cancer Center , Chiba, 260-8717,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiaki","family":"Inagaki","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Kindai University Faculty of Medicine , Sakai, 590-0197,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomomi","family":"Kashiwada","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Saga-Ken Medical Center Koseikan , Saga, 840-8571,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiaki","family":"Mihara","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Showa Medical University Fujigaoka Hospital , Yokohama, 227-8501,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akinori","family":"Sugaya","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Ibaraki Prefectural Central Hospital , Kasama, 309-1793,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Suwa","sequence":"additional","affiliation":[{"name":"Department of Surgery, Gastroenterological Center, Yokohama City University Medical Center , Yokohama, 232-0024,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Ohta","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Kansai Rosai Hospital , Amagasaki, 660-0064,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidekazu","family":"Kuramochi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, NTT Medical Center Tokyo , Tokyo, 141-8625,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kotoe","family":"Oshima","sequence":"additional","affiliation":[{"name":"Division of Gastrointestinal Oncology, Shizuoka Cancer Center , Sunto-Gun, 411-8777,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Yuki","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Hokkaido University Hospital , Sapporo, 060-8648,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manabu","family":"Shiozawa","sequence":"additional","affiliation":[{"name":"Department of Surgery, Kanagawa Cancer Center , Yokohama, 241-8515,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihito","family":"Tsuji","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Faculty of Medicine, Kagawa University , Kagawa, 761-0793,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5572-743X","authenticated-orcid":false,"given":"Kei","family":"Muro","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Aichi Cancer Center Hospital , Nagoya, 464-8681,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Ichikawa","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Showa Medical University Fujigaoka Hospital , Yokohama, 227-8501,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Fujii","sequence":"additional","affiliation":[{"name":"Japan Clinical Cancer Research Organization (JACCRO) , Tokyo, 101-0051,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0163-7543","authenticated-orcid":false,"given":"Yu","family":"Sunakawa","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, St. Marianna University School of Medicine , Kawasaki, 216-8511,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,2,27]]},"reference":[{"key":"2026032213320480800_oyag068-B1","first-page":"1","article-title":"The evolving treatment landscape in BRAF-V600E-mutated metastatic colorectal cancer","volume":"42","author":"Tabernero","year":"2022","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2026032213320480800_oyag068-B2","doi-asserted-by":"crossref","first-page":"102541","DOI":"10.1016\/j.ctrv.2023.102541","article-title":"European expert panel consensus on the clinical management of BRAFV600E-mutant metastatic colorectal cancer","volume":"115","author":"Martinelli","year":"2023","journal-title":"Cancer Treat Rev"},{"key":"2026032213320480800_oyag068-B3","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1056\/NEJMoa1908075","article-title":"Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer","volume":"381","author":"Kopetz","year":"2019","journal-title":"N Engl J Med"},{"key":"2026032213320480800_oyag068-B4","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1038\/s41591-024-03443-3","article-title":"Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial","volume":"31","author":"Kopetz","year":"2025","journal-title":"Nat Med"},{"key":"2026032213320480800_oyag068-B5","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1007\/s10147-025-02899-8","article-title":"Japanese Society for Cancer of the colon and Rectum (JSCCR) guidelines 2024 for the treatment of colorectal cancer","volume":"30","author":"Kinugasa","year":"2025","journal-title":"Int J Clin Oncol"},{"key":"2026032213320480800_oyag068-B6","doi-asserted-by":"crossref","first-page":"100055","DOI":"10.1016\/j.esmorw.2024.100055","article-title":"Safety and efficacy of encorafenib\u2013cetuximab combination in BRAFV600E-mutated metastatic colorectal cancer: real-world evidence from the CONFIDENCE Spanish multicenter study","volume":"5","author":"Fern\u00e1ndez-Montes","year":"2024","journal-title":"ESMO Real World Data Digit Oncol"},{"key":"2026032213320480800_oyag068-B7","doi-asserted-by":"crossref","first-page":"100603","DOI":"10.1016\/j.esmoop.2022.100603","article-title":"Real-world first-line treatment of patients with BRAF(V600E)-mutant metastatic colorectal cancer: the CAPSTAN CRC study","volume":"7","author":"Martinelli","year":"2022","journal-title":"ESMO Open"},{"key":"2026032213320480800_oyag068-B8","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.2217\/fon-2023-0209","article-title":"The BEETS (JACCRO CC-18) trial: an observational and translational study of BRAF-mutated metastatic colorectal cancer","volume":"19","author":"Inagaki","year":"2023","journal-title":"Future Oncol"},{"key":"2026032213320480800_oyag068-B9","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa2501912","article-title":"Encorafenib, cetuximab, and mFOLFOX6 in BRAF-mutated colorectal cancer","volume":"392","author":"Elez","year":"2025","journal-title":"N Engl J Med"},{"key":"2026032213320480800_oyag068-B10","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1200\/JCO.22.01693","article-title":"ANCHOR CRC: results from a single-arm, phase II study of encorafenib plus binimetinib and cetuximab in previously untreated BRAFV600E-mutant metastatic colorectal cancer","volume":"41","author":"Van Cutsem","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026032213320480800_oyag068-B11","doi-asserted-by":"crossref","first-page":"3261","DOI":"10.1038\/s41591-024-03235-9","article-title":"Molecular profiling of BRAF-V600E-mutant metastatic colorectal cancer in the phase\u20093 BEACON CRC trial","volume":"30","author":"Kopetz","year":"2024","journal-title":"Nat Med"},{"key":"2026032213320480800_oyag068-B12","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1158\/1078-0432.CCR-16-0140","article-title":"BRAF V600E mutant colorectal cancer subtypes based on gene expression","volume":"23","author":"Barras","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2026032213320480800_oyag068-B13","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1158\/1078-0432.CCR-19-3579","article-title":"BRAF-mutant transcriptional subtypes predict outcome of combined BRAF, MEK, and EGFR blockade with dabrafenib, trametinib, and panitumumab in patients with colorectal cancer","volume":"26","author":"Middleton","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2026032213320480800_oyag068-B14","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1158\/2159-8290.CD-11-0341","article-title":"EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib","volume":"2","author":"Corcoran","year":"2012","journal-title":"Cancer Discov"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag068\/67166378\/oyag068.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/4\/oyag068\/67166378\/oyag068.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/4\/oyag068\/67166378\/oyag068.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,22]],"date-time":"2026-03-22T17:32:09Z","timestamp":1774200729000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag068\/8501981"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,27]]},"references-count":14,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,3,9]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag068","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4]]},"published":{"date-parts":[[2026,2,27]]},"article-number":"oyag068"}}